BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 24443315)

  • 1. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
    Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
    Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
    Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
    Tamura R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
    Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Back to the future: proceedings from the 2010 NF Conference.
    Huson SM; Acosta MT; Belzberg AJ; Bernards A; Chernoff J; Cichowski K; Gareth Evans D; Ferner RE; Giovannini M; Korf BR; Listernick R; North KN; Packer RJ; Parada LF; Peltonen J; Ramesh V; Reilly KM; Risner JW; Schorry EK; Upadhyaya M; Viskochil DH; Zhu Y; Hunter-Schaedle K; Giancotti FG
    Am J Med Genet A; 2011 Feb; 155A(2):307-21. PubMed ID: 21271647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
    Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
    BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
    Plotkin SR; Blakeley JO; Evans DG; Hanemann CO; Hulsebos TJ; Hunter-Schaedle K; Kalpana GV; Korf B; Messiaen L; Papi L; Ratner N; Sherman LS; Smith MJ; Stemmer-Rachamimov AO; Vitte J; Giovannini M
    Am J Med Genet A; 2013 Mar; 161A(3):405-16. PubMed ID: 23401320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schwannomatosis: the overlooked neurofibromatosis?
    Koontz NA; Wiens AL; Agarwal A; Hingtgen CM; Emerson RE; Mosier KM
    AJR Am J Roentgenol; 2013 Jun; 200(6):W646-53. PubMed ID: 23701098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes.
    Perez-Becerril C; Evans DG; Smith MJ
    Hum Mutat; 2021 Oct; 42(10):1187-1207. PubMed ID: 34273915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis: part 2--clinical management.
    Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
    Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
    Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
    J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of neurofibromatosis-associated tumours.
    Lin AL; Gutmann DH
    Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schwannomatosis: a Realm Reborn: year one.
    Planet M; Kalamarides M; Peyre M
    Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
    Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.
    Kalamarides M; Acosta MT; Babovic-Vuksanovic D; Carpen O; Cichowski K; Evans DG; Giancotti F; Hanemann CO; Ingram D; Lloyd AC; Mayes DA; Messiaen L; Morrison H; North K; Packer R; Pan D; Stemmer-Rachamimov A; Upadhyaya M; Viskochil D; Wallace MR; Hunter-Schaedle K; Ratner N
    Acta Neuropathol; 2012 Mar; 123(3):369-80. PubMed ID: 22083253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
    Vranceanu AM; Merker VL; Park E; Plotkin SR
    J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What to know about schwannomatosis: a literature review.
    Schraepen C; Donkersloot P; Duyvendak W; Plazier M; Put E; Roosen G; Vanvolsem S; Wissels M; Bamps S
    Br J Neurosurg; 2022 Apr; 36(2):171-174. PubMed ID: 33263426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.